GlassScriptPhysician profile
Carmen I Sanchez
NPI 1558508788
$774.97
in general payments reported to CMS, 2019-2025
19 companies · $165 in 2025
The $165 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.72 · 2020: $28.94 · 2021: $109 · 2022: $17.28 · 2023: $178 · 2024: $257 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588 · Travel and Lodging: $12.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.01 |
| Travel and Lodging | $12.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $226.17 | 2024 | |
| Lilly USA, LLC | $112.70 | 2021-2024 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $61.49 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $49.30 | 2021-2023 | Seglentis, Livalo |
| Novo Nordisk INC | $48.68 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $44.30 | 2025 | |
| Revance Therapeutics, INC. | $28.91 | 2025 | Daxxify |
| Integra Lifesciences Corporation | $26.88 | 2025 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Medtronic Vascular, INC. | $19.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.42 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.98 | 2025 | Jornay Pm |
| Merz North America, INC. | $17.42 | 2020 | |
| Trevena, INC. | $17.28 | 2022 | |
| Acella Pharmaceuticals, LLC | $16.28 | 2025 | NP Thyroid 60 |
| Tris Pharma INC | $15.31 | 2025 | Dyanavel Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $15.16 | 2025 | Contrave, Onzetra Xsail |
| Pfizer INC. | $14.70 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $11.75 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.